Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical AffairsGlobeNewsWire • 10/01/24
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/30/24
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024GlobeNewsWire • 08/26/24
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceGlobeNewsWire • 08/06/24
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of DirectorsGlobeNewsWire • 06/13/24
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™GlobeNewsWire • 06/06/24
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceGlobeNewsWire • 05/21/24
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisGlobeNewsWire • 05/14/24
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™GlobeNewsWire • 05/07/24
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/06/24
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceGlobeNewsWire • 03/27/24
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewsWire • 03/12/24
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to DeclineZacks Investment Research • 03/07/24
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsGlobeNewsWire • 02/27/24
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisGlobeNewsWire • 02/04/24
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing CholangitisGlobeNewsWire • 11/13/23
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/09/23
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?Zacks Investment Research • 11/09/23
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/07/23
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1GlobeNewsWire • 11/06/23
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 10/31/23